Tags : Eighth

Biosimilars Regulatory

Sandoz’s Ziextenzo (pegfilgrastim) Receives EU Approval for Reduction in Duration

 Shots: The approval is based on non-inferiority data with the reference biologic (Neulasta) showing biosimilarity in terms of safety, efficacy and quality Ziextenzo is a long-lasting form of filgrastim indicated to reduce duration of neutropenia and occurrence of febrile neutropenia in adult treated with cytotoxic (anti-cancer) CT Sandoz has received eight biosimilars approval worldwide, with […]Read More